<DOC>
	<DOCNO>NCT00336310</DOCNO>
	<brief_summary>The purpose study determine whether new-brand repaglinide effective treatment type 2 diabetes patient .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Parallel , Comparative Study Evaluate Efficacy Safety Antidiabetic Agent Repaglinide Treatment Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description>This study design evaluate efficacy safety new-brand repaglinide X® comparison Novonorm® treatment type 2 diabetes mellitus patient . Mentally competent patient age 30 75 year old Taiwan either sex type 2 diabetes mellitus include . All eligible subject randomize treatment group 1:1 ratio . The treatment consist either X® Novonorm® tid meal 12 week treatment . The primary endpoint include net change HbA ! c , fast plasma glucose ( FPG ) postprandial plasma glucose ( PPG ) end 12th week evaluation compare baseline visit . Also , safety profile include adverse event ( hypoglycemia ) incidence , blood pressure , liver , kidney function test monitor .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Mentally competent adult either sex age 3075 year old Patients type 2 diabetes mellitus diagnose 25 year age Patients poor glycemic control diet exercise least 1 month stable dose metformin least 3 month study ; poor glycemic control define : Glycosylated hemoglobin A1c ( HbA1c ) 7.111.0 % Patients sign write informed consent form Patients type 1 diabetes mellitus ( insulin¬dependent ) Patients take medication possibly affect significantly intestinal motility absorption nutrient . Female patient pregnant try become pregnant lactating study Patients alcohol , drug medication abuse consider investigator Patients impair liver function ( AST , ALT＞2.5× upper limit normal ) Patients impaired kidney function ( serum creatinine＞3.0 mg/dl ) Patients unstable cardiovascular condition ( e.g. , New York Heart Association functional class III IV congestive heart failure history myocardial infarction stroke ) Patients emphysema chronic bronchitis Patients diabetic ketoacidosis Patients hepatic cirrhosis Patients ongoing inflammatory bowel disease , colonic ulceration , partial intestinal obstruction Patients predispose intestinal obstruction Patients chronic intestinal disease relate mark disorder digestion absorption Patients clinically significant medical condition may deteriorate clinically due gastrointestinal gas increase Patients history lactic acidosis Patients history allergic repaglinide Patients take hypoglycemic agent except metformin within 3 month study Patients participate investigational drug trial within 1 month enter study Patients serious disease consider investigator condition enter trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Treatment</keyword>
	<keyword>Repaglinide</keyword>
</DOC>